Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Liabilities and Shareholders Equity (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $55.9 million as the latest value for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 27.48% to $55.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $212.1 million through Jan 2026, down 7.38% year-over-year, with the annual reading at $55.2 million for FY2025, 7.91% down from the prior year.
  • Liabilities and Shareholders Equity for Q1 2026 was $55.9 million at PharmaCyte Biotech, roughly flat from $56.0 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $91.9 million in Q1 2022, with the low at $43.8 million in Q1 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $69.1 million, with a median of $71.4 million recorded in 2024.
  • The sharpest move saw Liabilities and Shareholders Equity surged 1216.56% in 2022, then tumbled 38.58% in 2025.
  • Over 5 years, Liabilities and Shareholders Equity stood at $82.3 million in 2022, then dropped by 4.21% to $78.9 million in 2023, then crashed by 30.15% to $55.1 million in 2024, then grew by 1.59% to $56.0 million in 2025, then fell by 0.18% to $55.9 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $55.9 million, $56.0 million, and $45.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.